Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
Followers
16K
Following
32K
Media
3K
Statuses
35K
Personal acc. Med Onc. A/Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNykq3 Talks- https://t.co/anav3AIZjO
Kingston, Ontario
Joined September 2015
Code Break or Code Blue?.Our latest in Cancer Journal where we discuss the Codebreak 300 trial of Sotorasib in CRC in terms of trial design issues and policy implications. This trial is also unique in terms of selection of the right dose. Precision oncology doesn’t mean just
0
2
11
Don’t miss out on this wonderful opportunity. It’s a high-impact fellowship that’ll allow you to learn health service and cancer policy research. Our current @csoncol fellow @SamuelXStevens started in July and already has his first publication!
acsjournals.onlinelibrary.wiley.com
Although no survival benefit over standard therapies has been established, the combination of sotorasib plus panitumumab recently received full US Food and Drug Administration approval for use in...
🚨 Fellowship Opportunity! . The 2026 CSO Fellowship in Health Services Research is now accepting applications. Apply today: Based at Queen's University in Kingston, Canada, this 1-year Fellowship is an opportunity to build health services research
0
2
7
RT @barttels2: @oncology_bg Lot of things turned on their head here. Enjoy. Overall survival may have been moved to the back of the bus.….
0
1
0
RT @Eddie_Cliff: @oncology_bg The crossover comments from FDA are disappointing on multiple levels - appropriate crossover is also not conf….
0
3
0
The latest FDA Guidance emphasizes OS to rule out harm. It’s better than nothing but OS should be viewed as an efficacy endpoint. It’s not to rule out harm but also to confirm that the drugs actually benefit people. The crossover guidance is misguided. It says “in general it
3
4
18
Emphasis on overall survival is good but as a safety endpoint or as an efficacy endpoint? Safety implies we don’t want to see worse OS. Efficacy implies we want to see improved OS.
NEW: FDA releases draft guidance on overall survival assessment in oncology trials, with an emphasis on analyzing overall survival as a pre-specified safety endpoint.
1
1
12
Dr. Teuwen @lateuwen is spending a month with our team @queenscce @queensoncology @QueensUHealth @QueensuSCRI for her fellowship. She has made quite a career transition from studying mice in Belgium to cancer care in Malawi. Very excited to hear this talk!
0
3
7
Number of drug approvals is not a surrogate for improved patient outcomes. We don’t just need more drugs, we need drugs that improve outcomes. The pendulum had swung too far to approving any drug. Some restoring of balance is needed.
Nice to know that the @WSJ editorial board has turned itself over to become an arm of pharma. Does FDA Commissioner Marty Makary want to accelerate life-saving drugs as he claims? via @WSJopinion.
3
10
41
Encouraging data with policy implications for Europe’s “right to be forgotten” regulations for AYA cancer survivors. @Winette_vdGraaf.
thelancet.com
These results can serve as a basis for the reappraisal of current RTBF regulations for AYA solid malignancy survivors in the Netherlands, which can have important implications for other European...
0
1
11
You can’t say what’s satire and what’s not anymore.
Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S.
1
1
14
This is a very well researched and well written article on toxicities of cancer drugs.
8
36
157
MOGA ASM 2023 has been one of the most meaningful and productive conferences that I’ve spoken at. 2 years later, we got this wonderful doc as our @csoncol fellow!.Notwithstanding some questionable things that we did beyond midnight as shown in this picture, it’s still one of the
Thanks for the tweet @DKarikios! Sad to miss this year’s @MOGA_ORG ASM but timely to reflect on where the fledgling @csoncol movement has come since that fateful ASM where I first met @oncology_bg! Towards #outcomesthatmatter in the Western Pacific, together.
2
0
4
Delighted to join the editorial board of @JNCI_Now as an Associate Editor. Looking forward to contributing positively and meaningfully to the fraternity.
academic.oup.com
5
4
54
RT @oncology_bg: Our new editorial published in @JNCI_Now where we discuss how to improve the success rates of phase 3 oncology trials. Led….
0
27
0
This is good news. I want VP to have a longer term at the FDA. I still remain hopeful about seeing some positive changes, fingers crossed.
Happy Saturday. Vinay Prasad returns to the FDA, weeks after his ouster | STAT
3
0
13
Very salient points in this thoughtful critique of the recent FDA accelerated approval of ONC201 in a biomarker selected subgroup of glioma.
⚡️Today's FDA Accelerated Approval of ONC201 for H3 K27M-Mutant Diffuse Midline Glioma is TROUBLING!. ONC201 is celebrated as a breakthrough in the treatment of one of the most devastating brain cancers, but the reality is very different 👇. Best available data show that this.
0
0
7
RT @StasLazarev: ⚡️Today's FDA Accelerated Approval of ONC201 for H3 K27M-Mutant Diffuse Midline Glioma is TROUBLING!. ONC201 is celebrated….
0
12
0